At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses recent developments in the research of kidney cancer management.
Identification of cancer subtypes through molecular profiling may guide future trial design and management options. Combination therapies have the potential to improve efficacy. There are a variety of online resources for patients interested in participating in clinical trials.
Year of Production: